DE68925974D1 - Konjugate zur steigerung der durchlässigkeit der gefässe - Google Patents

Konjugate zur steigerung der durchlässigkeit der gefässe

Info

Publication number
DE68925974D1
DE68925974D1 DE68925974T DE68925974T DE68925974D1 DE 68925974 D1 DE68925974 D1 DE 68925974D1 DE 68925974 T DE68925974 T DE 68925974T DE 68925974 T DE68925974 T DE 68925974T DE 68925974 D1 DE68925974 D1 DE 68925974D1
Authority
DE
Germany
Prior art keywords
species
vasoactive
conjugates
disclosed
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68925974T
Other languages
English (en)
Other versions
DE68925974T2 (de
Inventor
Alan Epstein
Michael Glovsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of DE68925974D1 publication Critical patent/DE68925974D1/de
Publication of DE68925974T2 publication Critical patent/DE68925974T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE68925974T 1988-10-11 1989-10-11 Konjugate zur steigerung der durchlässigkeit der gefässe Expired - Lifetime DE68925974T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25551388A 1988-10-11 1988-10-11
US41778289A 1989-10-04 1989-10-04
PCT/US1989/004513 WO1990003801A1 (en) 1988-10-11 1989-10-11 Vasopermeability-enhancing conjugates

Publications (2)

Publication Number Publication Date
DE68925974D1 true DE68925974D1 (de) 1996-04-18
DE68925974T2 DE68925974T2 (de) 1996-11-14

Family

ID=26944744

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68925974T Expired - Lifetime DE68925974T2 (de) 1988-10-11 1989-10-11 Konjugate zur steigerung der durchlässigkeit der gefässe

Country Status (7)

Country Link
EP (1) EP0438497B1 (de)
JP (1) JP2961173B2 (de)
AT (1) ATE135236T1 (de)
AU (1) AU627785B2 (de)
DE (1) DE68925974T2 (de)
IL (1) IL91933A (de)
WO (1) WO1990003801A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090105A1 (en) * 1990-08-29 1992-03-01 Jean-Paul Soulillou Protein polyligands joined to a stable protein core
ATE218889T1 (de) * 1990-11-09 2002-06-15 Stephen D Gillies Cytokine immunokonjugate
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
ES2193143T3 (es) * 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
AT409929B (de) * 1997-03-07 2002-12-27 Tritthart Helmut A Dr Polymere-infusionslösung zur anwendung bei der diagnose von tumoren, gegebenenfalls zu deren behandlung
CA2219961C (en) * 1998-01-09 2010-06-01 The University Of Southern California Vasopermeability enhancing peptide of human interleukin-2 and immunoconjugates thereof
DE19824653A1 (de) * 1998-02-25 1999-08-26 Schering Ag Nekrose-affine Verbindungen und ihre Verwendung zur Herstellung von Präparaten zur Pharmakotherapie
HUP0101468A2 (hu) 1998-03-31 2001-08-28 Du Pont Pharmaceuticals Company Angiogenetikus rendellenességek leképzésére alkalmas szerek
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
JP2002520297A (ja) 1998-07-13 2002-07-09 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム アミノリン脂質に結合する治療結合体を用いる癌処置方法
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
IL142958A0 (en) 1998-12-18 2002-04-21 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
CA2349333A1 (en) 1998-12-18 2000-06-22 Du Pont Pharmaceuticals Company Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
US6630120B1 (en) * 1999-03-08 2003-10-07 Alkermes, Inc. Agents to increase the uptake of pharmaceuticals and diagnostic substances into solid tumors
DK1200479T3 (da) 1999-08-09 2006-05-15 Emd Lexigen Res Ct Corp Multiple cytokin-antistof-komplekser
EP1263776A2 (de) * 2000-03-16 2002-12-11 University Of Pittsburgh Peptide, die spezifisch die endothelzellen aus tumoren markieren
IT1318485B1 (it) * 2000-04-21 2003-08-25 Bracco Spa Uso di derivati di acidi biliari coniugati con complessi di ionimetallici nella visualizzazione diagnostica di sistemi microvascolari
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US20060222653A1 (en) * 2004-11-12 2006-10-05 Xencor, Inc. Antibodies operably linked to selected chemoattractants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753894A (en) * 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
AU587600B2 (en) * 1985-01-11 1989-08-24 Regents Of The University Of California, The Method for preserving liposomes
US4724213A (en) * 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-1 and diagnostic antibody produced thereby
US4724212A (en) * 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-2 and diagnostic antibody produced thereby
US4771128A (en) * 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
US4753895A (en) * 1987-02-24 1988-06-28 Hughes Aircraft Company Method of forming low leakage CMOS device on insulating substrate

Also Published As

Publication number Publication date
DE68925974T2 (de) 1996-11-14
AU627785B2 (en) 1992-09-03
JPH04503945A (ja) 1992-07-16
EP0438497B1 (de) 1996-03-13
WO1990003801A1 (en) 1990-04-19
ATE135236T1 (de) 1996-03-15
AU4424589A (en) 1990-05-01
EP0438497A4 (en) 1992-02-26
JP2961173B2 (ja) 1999-10-12
EP0438497A1 (de) 1991-07-31
IL91933A (en) 1994-12-29

Similar Documents

Publication Publication Date Title
DE68925974D1 (de) Konjugate zur steigerung der durchlässigkeit der gefässe
EP2347770B1 (de) Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
ATE107514T1 (de) Stabilisierte protein- oder peptidkonjugate.
EP0861667A3 (de) Partikelförmige Mittel
Fiume et al. Drug targeting in antiviral chemotherapy: A chemically stable conjugate of 9-β-d-arabinofuranosyl-adenine 5'-monophosphate with lactosaminated albumin accomplishes a selective delivery of the drug to liver cells
IL97411A (en) Pharmaceutical formulations comprising hapten-modified diagnostic or therapeutic agents
DE3786005T3 (de) Träger zur Freisetzung mit einem an eine amphiphile Substanz gekoppelten Wirkstoff.
ATE216402T1 (de) Opioid-konjugate mit endogenen trägerproteinen
WO1998022141A2 (en) Enhanced effects for hapten conjugated therapeutics
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
WO1999056723A3 (en) Hemoglobine-haptoglobin complexes for targeted drug delivery
ATE166233T1 (de) Verwendung von substanzen in partikelform
CA2000479A1 (en) Vasopermeability-enhancing conjugates
Ely Dermatologic therapies you’ve probably never heard of
Baciu Nervolus Control of the Phagocytic System
Maeda et al. Antitumor activity of some bacterial proteases: eradication of solid tumors in mice by intratumor injection
Gruber et al. An implantable pump for intrarenal infusion of immunosuppressants in a canine autotransplant model
JPH06293631A (ja) ケラチン加水分解物を担体として用いたドラッグデリバリーシステム
SU1033141A1 (ru) Способ лечени деструктивного панкреатита
RU94045008A (ru) Способ преодоления гематоэнцефалического барьера
Yoshioka et al. Selective enhancer of tumor vascular permeability for optimization of cancer chemotherapy
JPH04501705A (ja) 腫瘍の組み合せ処理のためのフィブリン溶解剤の使用
TH51752A (th) องค์ประกอบของยาร่วมฤทธิ์และวิธีการสำหรับการบำบัดรักษาการเจริญเติบโตของเนื้องอกหรือมะเร็ง และสำหรับทำให้การสร้างเม็ดเลือดกลับดีขึ้น หรือการเพิ่มเม็ดเลือด

Legal Events

Date Code Title Description
8364 No opposition during term of opposition